Prestige Consumer Healthcare Inc.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $1.1B
- Net income
- $190.3M
- Total assets
- $3.5B
- Market cap
- $2.2B
- Gross margin
- 54.7%
- Operating margin
- 28.4%
- Net margin
- 17.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.1B
- Cost of revenue
- $493.1M
- Gross profit
- $595.6M
- Operating expenses
- $286.2M
- Operating income
- $309.4M
- Income tax
- $67.2M
- Net income
- $190.3M
- EPS (basic)
- $3.93
- EPS (diluted)
- $3.91
Balance sheet
- Total assets
- $3.5B
- Current assets
- $431.5M
- Total liabilities
- $1.6B
- Current liabilities
- $120.9M
- Shareholders’ equity
- $1.9B
Cash flow
- Operating cash flow
- $257.6M
- Investing cash flow
- -$136.8M
- Financing cash flow
- -$156.1M
- Net cash flow
- -$34.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.2B
- P/E ratio
- 12.2
- EPS (diluted)
- $3.91
- Shares outstanding
- 46.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 10, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $190.3M in FY2026.
- Revenue grew 0% from FY2022 to FY2026.
- Gross margin of 54.7%, net margin 17.5%.
- Trading 46% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 12.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Prestige Consumer Healthcare Inc..
Write a review
News about Prestige Consumer Healthcare Inc.
News & sentiment via Polygon.io
